Citations

Clear

68 citation(s) found for "Anderson, John".

The Genomic Landscape and Treatment Outcomes Associated with CDKN2A/MTAP Loss in Patients with Non–Small Cell Lung Cancer
Vokes, Natalie I. , Symons, Jessica L. , Rhead, Brooke , Hong, Lingzhi , Shah, Pooja A. , Lai, Zhongwu , Zhu, Zhou , Treviño, Santiago , Iorgulescu, J. Bryan , Wu, Jia , Leventakos, Konstantinos , Zhu, Zhou , Bryan, Julian , Zhang, Jianjun , Gibbons, Don L , Heymach, John V , Stewart, Ross , Iyer, Sonia , Leventakos, Konstantinos , Fragkogianni, Stamatina , Chao, Calvin Y. , Rodon, Jordi , Zhang, Jianjun , Heymach, John V. , Fragkogianni, Stamatina , Vokes, N.

Mayo Clinic

Clinical Cancer Research | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF14

10.1158/1078-0432.ccr-26-0771 | PMID 42507545 Get It

Abstract Purpose: Homozygous deletion of the 9p21 locus, containing CDKN2A/B and MTAP [CDKN2A/MTAP deletion (CMdel)], underlies emerging therapeutic strategies, including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcome associations of CMdel in non–small cell lung cancer (NSCLC) remain incompletely defined. Experimental Design: We analyzed Tempus Lens records with paired DNA (xT) and RNA (xR) sequencing. After quality filtering (purity ≥40%), 16,947 patients were included in the primary dataset, and 10,996 were included in the validation dataset and stratified by deletion status [CMdel vs. CM wild-type (CMwt)]. IFN status was defined by IFN-kappa (IFNK) expression [log2(TPM + 1)] using the 25th percentile of CMwt as the threshold. Immune composition was inferred by quanTIseq. First-line regimens were grouped as immune checkpoint inhibitor (ICI) monotherapy, ICI chemotherapy, chemotherapy, or tyrosine kinase inhibitors (TKI). Best response and time to next treatment (TTNT) with risk-set adjustment and 18-month truncation were assessed. Results: CMdel occurred in 11.7% (n = 1,991) and 15% (n = 1,676), respectively, and was enriched in mucinous histology, stage IV disease, and never smokers. CMdel was associated with EGFR, TERT, and SMARCA4 alterations, whereas CMwt was associated with RB1, SETD2, and ARID2. More than 50% of CMdel tumors harbored targetable coalterations, enriched in EGFR/ALK/RET and relatively depleted in KRAS. CMdel tumors exhibited lower PD-L1, mutation burden, and immune infiltration. TTNT did not differ by CM status for ICI monotherapy or TKI but was shorter in CMdel for ICI chemotherapy and chemotherapy. Discordant and broad deletions were less common and had weaker TTNT association. IFNK-low expression marked immune-excluded subgroups with worse treatment outcomes. Conclusions: CDKN2A/MTAP loss defines a prevalent, genomically distinct NSCLC subset enriched in actionable drivers. CMdel associates with worse outcomes to ICI/chemotherapy-containing regimens. These findings highlight convergent biology at 9p21 and support biomarker-guided development of PRMT5/MAT2A inhibitors in MTAP-deleted NSCLC.
ID #536 Reshaping tumour immunity in MYC-driven medulloblastoma
Draper, Benjamin, Thompson, Dean, You, Zhen, Hill, Rebecca, Jacques, Thomas, Ayrault, Olivier , Sorensen, P H, Anderson, John, Chesler, Louis, Clifford, Steve, Huang, Frank, Donovan, Laura, Draper, Benjamin , Thompson, Dean , Hill, Rebecca, Sørensen, Poul, Chesler, Louis , Clifford, Steve, Donovan, Laura

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.200 Get It

Abstract One of the most significant unmet clinical challenges in paediatric oncology is the development of novel therapeutic strategies for recurrent medulloblastoma (R-MB). MYC-driven MBs are defined as classically cold tumours with a low incidence of infiltrating immune cells, resulting in a therapeutic challenge. The identification of cell-cell interactions between tumour and immune cells may provide insight into critical intercellular communications and manipulations occurring within the tumour immune microenvironment (TME). We hypothesised that the key cell-cell interactions in MYC-driven primary and recurrent MB may reveal dominant immune-suppressive mechanisms and uncover targetable therapeutic vulnerabilities. Paired primary-recurrent bulk RNA-sequencing data, confirmed myeloid cells as the most infiltrating immune cell type in group3-MB and group4-MB. Comprehensive spatial phenotypic and cell-cell communication analyses corroborated this discovery, validating an increased incidence of macrophages in the matched-recurrent tumours. Subsequently, we used innovative algorithms for 10X MB single-cell data to predict interactions between tumour-cell ligands and immune-cell receptors within the TME; macrophages emerged as the core immune-cells involved in interactions throughout the TMEs, with the most significant ligand-receptor interaction and inflammatory response between MIF and CD74. In-depth immunohistochemistry analyses of primary and recurrent group3 and group4 tumours, and exhaustive tissue microarrays demonstrated expression of CD74 and MIF, with limited expression of CD74 within the brain. To investigate the therapeutic potential of CD74, we developed recurrent, immune competent MYC-driven medulloblastoma mouse models. Comprehensive deconvolution analysis confirmed the TME integrity of our models to mirror that of the human disease. Locoregional delivery and repeat dosing of a bioactive-CD74 peptide demonstrated complete tumour clearance in our immune-competent mouse models of primary and recurrent-MB, demonstrating the significant therapeutic potential of targeting the CD74-MIF axis in MYC-driven primary and recurrent MB. Key therapeutic vulnerabilities within the TME of MYC-driven MB have been identified, highlighting the CD74-MIF axis as a target for next-generation immunotherapies.
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
Sun, Zhuoxin, Rudin, Charles M., Khullar, Onkar V., Simone, Charles B., Oettel, Kurt, Kozono, David, Sunkara, Rajitha, Faller, Bryan, Hugec, Vladimir, Shipstone, Asheesh, McGary, Eric C., Clarke, Jeffrey M., Talsania, Ashita, Ding, Li, Heymach, J, Raez, Luis E., Malik, Shakun , Stinchcombe, T., Mandrekar, Sumithra J. , Bradley, J.D., Vokes, E., Gandara, David, Staley, Charles, Ramalingam, Suresh S., Chaft, Jamie E. , Sun, Zhuoxin, Rudin, Charles M. , Khullar, Onkar V. , Simone, Charles B. , Oettel, Kurt R., Kozono, David , Sunkara, Rajitha, Faller, Bryan A. , Isbell, James M. , Clarke, Jeffrey M., Govindan, Ramaswamy , Sands, Jacob , Heymach, John V. , Raez, Luis , Stinchcombe, Thomas E. , Gerber, David E. , Gandara, David R. , Ramalingam, Suresh S.

Mayo Clinic

JAMA | June 1, 2026 | Volume: 336 | Issue: 6 | Pages: 464

10.1001/jama.2026.8992 | PMID 42224490 Get It

Importance Preoperative and perioperative nivolumab improve event-free survival in resectable non–small cell lung cancer. The role of adjuvant nivolumab after upfront surgery is unknown. Objective To determine whether adjuvant nivolumab improves disease-free survival and overall survival in patients with resected non–small cell lung cancer with any tumor programmed death-ligand 1 (PD-L1) expression and in those with at least 50% PD-L1 expression. Design, Setting, and Participants This open-label, randomized phase 3 study enrolled participants from May 2016 through September 2019, with median follow-up of 72.6 months at the data cutoff in December 2025. The study was conducted at 378 centers in the US National Clinical Trials Network. Patients were identified through a screening trial. Those with resected tumors at least 4 cm and/or who were lymph node positive (N1/N2) were eligible for inclusion after completion of planned standard adjuvant therapy if the tumor was adenocarcinoma without sensitizing sequence variants in EGFR and ALK or squamous cell carcinoma. Intervention Patients were randomized in a 1:1 ratio to receive nivolumab 480 mg intravenously every 4 weeks for up to 1 year or standard care observation. Main Outcomes and Measures Co–primary end points were disease-free survival in the intention-to-treat population and in those with tumoral PD-L1 expression at least 50%. Overall survival was examined if the corresponding test of disease-free survival was statistically significant. Results A total of 466 patients (median age, 66 years; 241 [52%] male) were assigned to receive nivolumab and 469 (median age, 67 years; 245 [52%] male) to undergo standard care observation. The median duration of follow-up was 72.6 months. The trial was stopped for futility at 75% information. In the intention-to-treat population, median disease-free survival was 71.3 months with nivolumab and 68.8 months with observation (hazard ratio for progression or death, 0.97 [97% CI, 0.79-1.20]; [95% CI, 0.81-1.17]; 1-sided P = .39). In the subset of participants with PD-L1 of at least 50%, median disease-free survival was 89.8 months with nivolumab and 78.5 months with observation (hazard ratio for progression or death, 0.86 [98% CI, 0.55-1.34]; [95% CI, 0.59-1.25]; 1-sided P = .22). Conclusions and Relevance Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non–small cell lung cancer without sensitizing EGFR and ALK alterations when given after planned adjuvant chemotherapy and/or radiotherapy. Trial Registration Clinicaltrials.gov Identifier: NCT02595944
Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
Sun, Zhuoxin, Rudin, Charles M., Simone, Charles B., Oettel, Kurt R., Kozono, David E., Sands, Jacob, Heymach, J, Raez, Luis E., Malik, Shakun , Stinchcombe, Tom, Mandrekar, Sumithra J. , Vokes, Everett E., Gandara, David R., Staley, Charles A., Ramalingam, Suresh S., Khullar, Onkar, Chaft, Jamie E. , Rudin, Charles M. , Simone, Charles B. , Kozono, David , Govindan, Ramaswamy , Sands, Jacob , Heymach, John V. , Raez, Luis , Stinchcombe, Thomas E. , Gerber, David E. , Bradley, Jeffrey D. , Vokes, Everett E. , Gandara, David R. , Ramalingam, Suresh S. , Khullar, Onkar V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8000-8000

10.1200/jco.2026.44.16_suppl.8000 Get It

8000 Background: The NCI’s ALCHEMIST program has screened thousands of patients with resected lung adenocarcinoma for mutations in EGFR and ALK. EA5142 studied the efficacy of adjuvant nivolumab after standard of care adjuvant therapy in patients with resected lung adenocarcinoma without sensitizing EGFR and ALK alterations and squamous cell carcinoma. Methods: Patients enrolled in the ALCHEMIST screening trial (A151216) with resected NSCLC tumors at least 4 cm and/or lymph node positive (N1/2) (for lung adenocarcinoma, without sensitizing EGFR and ALK alterations), were centrally tested for tumor cell PD-L1 expression using the DAKO 28-8 clone. After completion of all planned adjuvant therapy (chemotherapy and/or post-operative radiation) patients were randomized 1:1 to adjuvant nivolumab 480 mg IV every 4 weeks for up to 1 year or best supportive care. Patients were stratified by tumor histology, stage (AJCC 7 th edition IB/IIA vs IIB/IIIA), prior adjuvant treatment, and PD-L1 status (<1% vs ≥1%). The primary study endpoints were disease free survival (DFS) in all patients and in patients with high tumor PD-L1 expression (≥50%). Overall survival was powered to be tested hierarchically, if DFS was positive. Results: Between July 2016 and October 2019, 935 patients were randomized across 378 sites. The treatment arms were balanced for age (median 66 years), sex (52% male), smoking status (10% never smoked), histology (29% squamous), stage and PD-L1 expression (29% PD-L1 high). With a median follow-up of 72.6 months, nivolumab did not improve DFS in the intention to treat population (median DFS 71.3 months vs. 68.8 months in observation arm), hazard ratio (HR) 0.97 (95% CI 0.81-1.17, p=0.78) or the PD-L1 ≥50% subset (median DFS 89.8 months vs. 78.5 months in observation arm), HR 0.86 (95% CI 0.59-1.25, p=0.43). In multivariate analysis, adjusting for age, gender, and smoking history, the DFS HR was 0.99 (95% CI 0.82-1.19, p=0.89) in all randomized patients and 0.82 (95% CI 0.56-1.2, p=0.31) in the PD-L1 ≥50% subset. As the primary recurrence endpoint included any lung cancer, including new primaries, a sensitivity analysis was performed excluding new primary lung cancers, DFS HR 0.97 (95% CI 0.80-1.18, p=0.76) in all patients and HR 0.88 (95% CI 0.60-1.30, p=0.52 in the ≥50% subset. The median duration of treatment with adjuvant nivolumab was 9.4 months (range 0-12.7 months). The most common reasons for nivolumab discontinuation were adverse event (29%), patient withdrawal (11%), and disease progression while on treatment (10%). Treatment related grade 3-5 toxicities were reported in 25% of patients: Grade 3: 23%, Grade 4: 2%, Grade 5: <1%. Conclusions: In patients with resected NSCLC (≥4cm or LN+, EGFR/ALK -) adjuvant nivolumab did not improve DFS, irrespective of tumor PD-L1 expression. Clinical trial information: NCT02595944 .
Abstract 4003: Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer
Bandyopadhyay, Rukhmini, Hong, Linghzi, Aldea, M, Li, Shenduo , Saad, Maliazurina B., Zhang, Jiexin, Showkatian, Eman , Arrechedera, Claudio A. , Han, Xiaoyu , Kitsel, Yuliya , Ismail, Sherif, Aminu, Muhammad , Zhu, Bo, Wu, Carol C., Carter, B., Chang, Joe Y, Liao, Zhongxing, Ghigna, Maria R., Tran, Hai T., Le, Xiuning, Cascone, Tina , Zhang, Bingnan, Araujo, Haniel A., Altan, Mehmet, Jaffray, David, Gibbons, Don L., Vaporciyan, Ara, Lee, J Jack, Kalhor, Neda , Haymaker, C, Wistuba, Ignacio, Heymach, John V., Lou, Yanyan, Vokes, N. , Soto, Luisa M. Solis, Zhang, Jianjun, Wu, Jia, Aldea, Mihaela , Zullo, Lodovica , Rojas, Frank R. , Saad, Maliazurina B. , Marin, Maricel C., Waqas, Muhammad , Ismail, Sohair , Zhu, Bo , Wu, Carol C. , Liao, Zhongxing , Ghigna, Maria‐Rosa , Soldato, Davide , Tran, Hai T., Le, Xiuning , Zhang, Bingnan , Araújo, Haniel Alves , Altan, Mehmet , Heeke, Simon , Gibbons, Don L , Vaporciyan, Ara A. , Lee, J Jack, Wistuba, Ignacio I. , Heymach, John V. , Soto, Luisa M. Solis , Zhang, Jianjun , Wu, Jia

Mayo Clinic

Cancer Research | May 15, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4003-4003

10.1158/1538-7445.am2026-4003 Get It

Abstract Background: Immune checkpoint inhibitors (ICIs) have improved survival in non-small-cell lung cancer (NSCLC), yet only a subset of patients benefits, and biomarkers like PD-L1 remain limited. Here, we introduce a deep learning-based pathomics framework that utilizes routine H&E-stained slides to predict therapeutic response and survival outcomes in ICI-treated metastatic NSCLC. Methods: The study included 797 ICI-treated NSCLC patients from MD Anderson, with external validation in 280 patients from Mayo Clinic, Gustave Roussy, and the Phase III ICI-naïve LUSC Lung-MAP S1400I trial receiving nivolumab with or without ipilimumab. Path-IO (Pathology-Driven Immunotherapy Optimization) comprised of four major steps: (1) pathologist-verified tissue classifier segmented WSIs into eight compartments—Background, Bronchi, Immune, Lung, Necrosis, Stroma, Tumor, and Vessel—and was validated on TCGA and CPTAC dataset; (2) a survival prediction module generating patient-level risk scores in the MD Anderson cohort and validated across external datasets; (3) integration of Path-IO risk scores with radiomics and clinical features to improve prognostic accuracy; and (4) biological interpretability analyses correlating Path-IO risk immune contexture from multiplex immunofluorescence and transcriptomic signatures from NanoString profiling. Results: Path-IO effectively stratified patients into high and low-risk groups with significant survival differences. In the MD Anderson cohort, it achieved HR = 2.11 (p &lt; 0.001) and HR = 2.51 (p &lt; 0.001) for OS in the discovery and validation sets, and HR = 2.34 (p &lt; 0.001) and HR = 1.87 (p &lt; 0.001) for PFS, respectively. In the multicenter Phase III Lung-MAP S1400I trial, Path-IO achieved HR = 1.78 (p = 0.016) for OS and HR = 2.76 (p = 0.006) for PFS. In external validation, it predicted outcomes in the Gustave Roussy (OS = 1.97, p = 0.003; PFS = 1.51, p = 0.046) and Mayo Clinic (OS = 2.46, p = 0.007; PFS = 2.45, p = 0.027) cohorts. Path-IO outperformed PD-L1 and remained an independent predictor in multivariate analysis (p &lt; 0.001). It enabled data-driven frontline selection between anti-PD-1 monotherapy and chemo-immunotherapy, offering guidance toward more personalized treatment decisions. Integration with radiomics and clinical features further improved predictive accuracy (OS 0.63→0.75; PFS C-index 0.58→0.70), while high Path-IO risk scores correlated with immune-cold phenotypes identified by multiplex immunofluorescence and NanoString transcriptomics. Conclusions: Path-IO demonstrates that deep learning models rooted in histopathologic architecture can generate interpretable and biologically informed survival predictions in NSCLC treated with ICIs. By integrating pathology, radiology, and clinical data, Path-IO provides complementary predictive value beyond established biomarkers such as PD-L1. Citation Format: Rukhmini Bandyopadhyay, Linghzi Hong, Mihaela Aldea, Shenduo Li, Lodovica Zullo, Frank R. Rojas, Maliazurina B. Saad, Maricel C. Marin, Muhammad Waqas, Jiexin Zhang, Eman Showkatian, Claudio A. Arrechedera, Xiaoyu Han, Yuliya Kitsel, Sherif Ismail, Muhammad Aminu, Bo Zhu, Carol C. Wu, Brett W. Carter, Joe Y Chang, Zhongxing Liao, Maria R. Ghigna, Davide Soldato, Hai T. Tran, Xiuning Le, Tina Cascone, Bingnan Zhang, Haniel A. Araujo, Mehmet Altan, Simon Heeke, David Jaffray, Don L. Gibbons, Ara Vaporciyan, J Jack Lee, Neda Kalhor, Cara Haymaker, Ignacio Wistuba, John V. Heymach, Yanyan Lou, Natalie Vokes, Luisa M. Solis Soto, Jianjun Zhang, Jia Wu. Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4003.
MDB-14. Reshaping tumour immunity in MYC-driven medulloblastoma
Draper, Ben, Thompson, Dean, Delaidelli, Alberto , Hill, Rebecca M. , Jacques, Tom, Faria, Claudia C , Ayrault, Olivier , Sorenson, Poul, Anderson, John, Chesler, Louis, Clifford, Steve, Huang, L Frank, Thompson, Dean , You, Zhen , Remeniuk, Bethany , Chesler, Louis , Clifford, Steve, Donovan, Laura K

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.213 Get It

Abstract One of the most significant unmet clinical challenges in paediatric oncology is the development of novel therapeutic strategies for recurrent medulloblastoma (R-MB). MYC-driven MBs are defined as classically cold tumours with a low incidence of infiltrating immune cells, resulting in a therapeutic challenge. The identification of cell-cell interactions between tumour and immune cells may provide insight into critical intercellular communications and manipulations occurring within the tumour immune microenvironment (TME). We hypothesised that the key cell-cell interactions in MYC-driven primary and recurrent MB may reveal dominant immune-suppressive mechanisms and uncover targetable therapeutic vulnerabilities. Paired primary-recurrent bulk RNA-sequencing data, confirmed myeloid cells as the most infiltrating immune cell type in group3-MB and group4-MB. Comprehensive spatial phenotypic and cell-cell communication analyses corroborated this discovery, validating an increased incidence of macrophages in the matched-recurrent tumours. Subsequently, we used innovative algorithms for 10X MB single-cell data to predict interactions between tumour-cell ligands and immune-cell receptors within the TME; macrophages emerged as the core immune-cells involved in interactions throughout the TMEs, with the most significant ligand-receptor interaction and inflammatory response between MIF and CD74. In-depth immunohistochemistry analyses of primary and recurrent group3 and group4 tumours, and exhaustive tissue microarrays demonstrated expression of both CD74 and MIF, with limited expression of CD74 within the brain. To investigate the therapeutic potential of CD74, we developed recurrent, immune competent MYC-driven medulloblastoma mouse models. Comprehensive deconvolution analysis confirmed the TME integrity of our models to mirror that of the human disease. Locoregional delivery and repeat dosing of a bioactive-CD74 peptide demonstrated complete tumour clearance in our immune-competent mouse models of primary and recurrent MB, demonstrating the significant therapeutic potential of targeting the CD74-MIF axis in MYC-driven primary and recurrent MB. Key cellular interactions and therapeutic vulnerabilities within the tumour microenvironment of MYC-driven medulloblastoma (MB) have been identified, highlighting the CD74-MIF axis as a target for next-generation immunotherapies.
MIF-CD74 signaling drives immune modulation in medulloblastoma
Draper, Benjamin, You, Zhen , Thompson, Dean, Guo, Xu, Morcavallo, Alaide , Pino, Diego Chillón, Nery, Carlos Lorenzo Gido, Shrestha, Sumana , Himsworth, Courtney , Delaidelli, A., Morlando, Sonia , Wade, Brandon, Gordon, Freya , Sanchez-Corrales, Yara, Hopkins, Bei, Monteiro, Natalie, Locke, Darren, Liu, Miao , Diaz, Jacob Torrejon, Greenslade, Kevin , Costa, Barbara Martins Da , Barker, Karen, Fletcher, Anya, Custódia, Carlos , Roque, Rafael , Jackson, Thomas, Barfoot, Regan, Castellano, Sergi , Hill, Rebecca M. , Saulnier, Olivier , Jacques, Thomas S, Faria, Claudia C , Ayrault, Olivier , Sorensen, Poul H., Anderson, John, Chesler, Louis, Huang, L Frank, Clifford, Steven C. , Castellano, Sergi , Jacques, Thomas S , Donovan, Laura K , Draper, Benjamin , Thompson, Dean , Bowers, Chantelle E , Delaidelli, Alberto , Remeniuk, Bethany , Sánchez-Corrales, Yara E. , Hopkins, Bei, Torrejon-Diaz, Jacob, Barker, Karen T. , Kwok, Colin , Ogunbiyi, Olumide Kayode , Richardson, Stacey , Jackson, Thomas John , Jacques, Thomas S. , Taylor, Michael D. , Anderson, John, Chesler, Louis , Huang, L Frank

Mayo Clinic

Neuro-Oncology | February 3, 2026 | Volume: 28 | Issue: 5 | Pages: 1316-1334

10.1093/neuonc/noag020 | PMID 41652893 Get It

Abstract Background Relapsed medulloblastoma remains a significant therapeutic challenge as it is near universally fatal. The tumor microenvironment of medulloblastoma plays a critical role in tumor progression, influencing tumor growth, immune evasion, and therapeutic resistance. We hypothesized that defining tumor-immune interactions in diagnostic and relapsed medulloblastoma may uncover mechanisms of immune evasion and identify novel therapeutic targets. Methods We analyzed paired primary and recurrent RNA-sequencing data from 140 medulloblastoma patients to profile immune cell composition and validate spatial relationships within the TME. To identify key tumor-immune interactions, we developed a novel algorithm to detect receptor-ligand pairs using single-cell RNA-sequencing data. These interactions were validated across RNA and proteomic datasets. Their functional significance was empirically demonstrated in newly developed immunocompetent models of recurrent medulloblastoma that closely recapitulate the human disease. Results We observed a shift toward a heightened immunosuppressive TME at relapse. Using our algorithm, we identified biologically significant receptor-ligand interactions, most notably MIF-CD74, constitutively expressed at RNA and protein levels across medulloblastoma subgroups, at diagnosis and relapse. Disrupting MIF-CD74 interactions led to significant alterations in the tumor microenvironment, highlighting its functional significance. Conclusions Our multifaceted approach identified key tumor-immune interactions in medulloblastoma. Among these, MIF-CD74 was validated as a targetable interaction, demonstrating the utility of our integrative approach for identifying novel therapeutic targets across multiple tumor types.
Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome
Herndon, Justine , McNeil, J Anderson, Winter, Salym, Chang, Alice Y. , McNeil, John Anderson, Chang, Alice Y

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 24, 2026 | Volume: 111 | Issue: 7 | Pages: 2064-2074

10.1210/clinem/dgag032 | PMID 41606802 Get It

Abstract Background Polycystic ovary syndrome (PCOS) affects 10% to 13% of individuals assigned female at birth (AFAB), although a greater prevalence is reported in transgender/gender diverse individuals (TGD) (23.8-38.8%). Testosterone therapy (TT) in TGD individuals is linked to worsening cardiovascular risk factors (CVRFs). Whether TT induces more adverse cardiometabolic changes in TGD with PCOS than TGD without PCOS remains uncertain. Objective To compare the effects of TT on CVRF in TGD with and without PCOS. Methods We retrospectively reviewed 373 records to identify 62 TGD with PCOS (withestablished guideline criteria) and 132 age-matched TGD without PCOS. Data included longitudinal anthropometric measurements, hormone and metabolic parameters, and CVRF before and after TT. Group comparison of PCOS vs without PCOS before and after TT was conducted via independent t-tests, Mann–Whitney-U, and Chi-square. Results At baseline, TGD with PCOS had significantly greater body mass index (BMI), obesity prevalence, and, after controlling for BMI, baseline metformin use. There were no significant differences between TGD with and without PCOS when comparing intra-participant changes after TT. Controlling for BMI, TGD with PCOS on TT exhibited significantly greater hyperlipidemia prevalence, alanine transaminase (ALT) levels, and bioavailable testosterone concentrations than TGD without PCOS on TT. Conclusion Greater baseline cardiometabolic risk was largely BMI-related in TGD with PCOS compared to TGD without PCOS. Only hyperlipidemia and elevated ALT were more prevalent during TT after adjusting for BMI. These findings support cardiometabolic monitoring during TT in all TGD individuals without significant increased risk with PCOS history.
P-1711. Attributable and Contributable Mortalities of Culture-Positive Invasive Aspergillosis in Unselected Patients with Hematologic Malignancies at a Tertiary Care Cancer Center: No Room for Complacency
Szvalb, Ariel D. , John, Teny, Matsuo, Takahiro, Jiang, Ying , Kontoyiannis, Dimitrios P, Wurster, Sebastian , Kontoyiannis, Dimitrios P.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1883 Get It

Abstract Background Invasive aspergillosis (IA) remains a common cause of both direct and contributable mortality in patients with hematologic malignancies (HM). Given the advances in antifungal management, it would be important to assess IA-attributable mortality (AM) and contributable mortality (CM), in addition to overall mortality (OM). Methods We retrospectively reviewed the records of 76 consecutive HM patients with proven/probable culture-positive IA (MSG/EORTC criteria) from 2015 to 2021. Death causality was adjudicated based on published criteria. AM was defined as death “due to” IA, while CM as death “due to” and “with” IA. OM encompassed death from any cause. Mortality rates and death causalities were evaluated at 2-, 4-, 6-, and 12-week intervals following IA diagnosis. A multivariate competing risk analysis was performed to identify independent risk factors for 6-week AM, with other death causalities as the competing event. To increase diagnostic accuracy, we excluded culture-negative, Aspergillus galactomannan (GM) positive cases, as GM can be produced by other hyalohyphomycetes. Results The median patient age was 60 years (61%). Lymphoma and multiple myeloma (L/MM) were the most common HM (40, 53%). The remaining patients had active leukemia. Twenty-nine patients (38%) had prior stem cell transplantation, and 10 (13%) had graft-versus-host disease. Aspergillus fumigatus was the most common species (47%). Six and 12-week mortality rates were 18.7% and 22.7% for AM, 42.7% and 49.3% for CM, and 45.3% and 53.3% for OM, respectively. Notably, 2-week OM was 27.6%. Lack of neutrophil recovery was the only independent risk factor for 6-week AM on multivariate analysis (OR=4.2, p=0.006). Conclusion Our findings reflect the modern reality of culture-documented IA, occurring mostly in HM patients with heavily pretreated L/MM not routinely receiving mold-active prophylaxis, and in those with active leukemia. In this real-life contemporary HM population, culture-positive IA was associated with high cumulative OM and CM. Understanding AM and CM rates could lead to more accurate sample size estimations in clinical mycology trials. Such trials should be pragmatic and assess antifungal failure at an earlier time point than the traditional 4-week mark post-diagnosis. Disclosures Dimitrios P. Kontoyiannis, MD, AbbVie, Inc: Advisory Board Participation|Astellas: Grant/Research Support|Basilea: Advisor/Consultant|Cidara, Inc: Advisory Board Participation|F2G, Inc: Advisor/Consultant|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Knight, Inc: Honoraria|Pfizer: Advisor/Consultant|Scynexis: Advisor/Consultant|TTF Pharmaceuticals, Inc: Advisor/Consultant|US-Israel Binational Sci Foundation: Grant/Research Support
Adopting Race‐Free Estimated Glomerular Filtration Rate for Unifying Medication‐Related Decision‐Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy
Wallace, J. , Rungkitwattanakul, Dhakrit , Khan, Rachel W. , Anderson, Lauren , Anderson, Erica , Nekidy, Wasim S. El , Nemecek, Branden D. , Meaney, Calvin J. , Prasad‐Reddy, Lalita , Salama, Lavinia , Hudson, Joanna Q. , Kane‐Gill, Sandra L. , Frazee, Erin N. , Anderson, Erica R , El Nekidy, Wasim S , Frazee, Erin N , Bzowyckyj, Andrew S , Kane-Gill, Sandra L , Peter, Wendy L. St.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | November 27, 2025 | Volume: 9 | Issue: 2 | Pages: No page available

10.1002/jac5.70153 | PMID 42009503 Get It

ABSTRACT Pharmacists play a critical role in optimizing medication use, especially in vulnerable populations such as those with chronic kidney disease (CKD). Despite strong evidence and recent guideline endorsements, many pharmacists continue to rely on the Cockcroft–Gault (C‐G) equation for medication dosing. This opinion paper issues a call to action for the widespread adoption of a race‐free, body surface area–adjusted estimated glomerular filtration rate (eGFR BSAadj ) for medication‐related decision‐making, as endorsed by the 2024 Kidney Disease: Improving Global Outcomes CKD guidelines and the National Kidney Foundation and the American Society of Nephrology Taskforce. Persistent variability in pharmacy practice, institutional protocols, and pharmacy education underscores the need for coordinated change. We urge health systems to integrate eGFR BSAadj into electronic health records and clinical decision support to enhance medication decision‐making; institutions to align protocols with contemporary eGFR‐based prescribing standards; pharmacy educators to contemporize and standardize education on kidney function assessment and medication dosing; and regulatory bodies to update licensure and board examinations. The pharmacy profession must act decisively in order to align with evidence‐based, equitable kidney‐related dosing practices and ensure optimal medication management for all patients.